CriticalClass III antiarrhythmics (Vaughan Williams)×Imidazole antifungal
Updated · Methodology
Mechanism
In the liver, CYP3A4 is the main enzyme that converts amiodarone into its active metabolite desethylamiodarone, and inhibitors of this enzyme may slow its metabolism and raise its levels (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The miconazole oral gel SmPC calls miconazole a clinically strong CYP3A4 inhibitor. It contraindicates oral miconazole with QT-prolonging drugs that this enzyme metabolises, because their higher levels can lead to QT prolongation and torsade de pointes (miconazole oral gel SmPC, AEMPS). Amiodarone meets both conditions: according to its own SmPC, it prolongs the QT interval, and CYP3A4 is the main enzyme that metabolises it (amiodarone SmPC, AEMPS). The gel SmPC, however, does not list amiodarone among its examples, and the documents report no study of this pair. Patients hold the gel in the mouth and then swallow it. After a 60 mg dose, plasma miconazole peaks at 31–49 ng/mL after about 2 hours, and its half-life is 20–25 hours (miconazole oral gel SmPC, AEMPS). Less than 1% of a cream dose is absorbed (miconazole cream SmPC, AEMPS). Each Spanish vaginal ovule contains 100 mg of miconazole with 300 mg of metronidazole. Their SmPC gives data for 1200 mg miconazole ovules: a peak plasma level of about 10–12 ng/mL, more than 100 times lower than after oral or intravenous use (vaginal ovule SmPC, AEMPS).
Symptoms
The miconazole oral gel summary of product characteristics (SmPC) links higher levels of QT-prolonging drugs to QT prolongation and potentially fatal torsade de pointes (miconazole oral gel SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amiodarone itself prolongs the QT interval on the electrocardiogram (ECG). New or worsened arrhythmias with amiodarone usually occur when drug interactions or electrolyte disturbances prolong the QT interval further (amiodarone SmPC, AEMPS). They include new ventricular fibrillation, incessant ventricular tachycardia and polymorphic ventricular tachycardia of the torsade de pointes type (amiodarone label, US Food and Drug Administration, FDA). Torsade de pointes causes palpitations, dizziness and fainting. In older people taking amiodarone, the heart rate may fall markedly, and heart block may occur (amiodarone SmPC, AEMPS).
Management
The combination is contraindicated for oral miconazole: the miconazole oral gel summary of product characteristics (SmPC) contraindicates oral miconazole with QT-prolonging drugs that the enzyme CYP3A4 metabolises. According to its own SmPC, amiodarone prolongs the QT interval, and CYP3A4 is the main enzyme that metabolises it (miconazole oral gel and amiodarone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Patients hold the gel in the mouth and then swallow it, so the contraindication also applies when the gel is used for oral or oesophageal candidiasis (miconazole oral gel SmPC, AEMPS). The Spanish amiodarone SmPC recommends avoiding CYP3A4 inhibitors during treatment (amiodarone SmPC, AEMPS). The US label says to avoid azole antifungals because amiodarone levels and the risk of torsade de pointes rise (amiodarone label, US Food and Drug Administration, FDA). Amiodarone interactions can persist for several weeks after it is stopped, as its half-life is 15–142 days (amiodarone FDA label). The miconazole cream SmPC does not mention QT-prolonging drugs or antiarrhythmics. It says that little miconazole reaches the blood, that clinically relevant interactions are rare and that caution is needed with vitamin K antagonists, oral antidiabetic drugs and phenytoin (miconazole cream SmPC, AEMPS). The vaginal ovules also contain metronidazole, and 20–25% of it is absorbed from the ovule. Their SmPC has a separate line: QT prolongation has been reported, particularly when metronidazole was given with QT-prolonging drugs (vaginal ovule SmPC, AEMPS). Before starting amiodarone, record an electrocardiogram (ECG), measure blood potassium and correct low potassium (amiodarone SmPC, AEMPS). The US label also says to correct low magnesium and calcium beforehand (amiodarone FDA label). If torsade de pointes occurs, do not give antiarrhythmics. Use ventricular pacing, and intravenous magnesium sulfate can also be given (amiodarone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- FDA: Pacerone (amiodarone) prescribing information (2025)– FDA, DailyMed setid 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (Upsher-Smith Laboratories), version 27, revised 07/2025, sections 5.4 and 7 (Table 1)
- AEMPS: Ficha técnica: Daktarin 20 mg/g gel oral, miconazol (nº registro 55962), sección 4.3 (2026)– AEMPS, CIMA, nº registro 55962 (Daktarin 20 mg/g gel oral, JNTL Consumer Health), revisión 06/2026, secciones 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Blasgina óvulos vaginales (nº registro 50441), sección 4.5 (2026)– AEMPS, CIMA, nº registro 50441 (Blasgina óvulos vaginales, Almirall), revisión 09/2026, secciones 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Miconazol crema (nº registro 50271), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 50271 (Daktarin 20 mg/g crema), revisión 06/2026, secciones 4.4, 4.5 y 5.2 (en el HTML de CIMA siguen al apartado 4.3, sin ancla propia)